After peanut allergy drug approval, Peninsula biotech munches sweet $200M deal
February 05, 2020 at 10:28 AM EST
The company also lined up a potential $400 million licensing deal for an experimental food allergy drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|